Author: "V. de Ledinghen" / Topic: medicine.medical_specialty - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"V. de Ledinghen"' showing total 170 results

Start Over Author "V. de Ledinghen" Topic medicine.medical_specialty

170 results on '"V. de Ledinghen"'

1. OC-06A cholestatic pattern predicts liver-related events in patients with nonalcoholic fatty liver disease

Author: Mauro Viganò, V. de Ledinghen, Rossana Porcasi, Rossella Zito, Rosaria Maria Pipitone, Elisabetta Bugianesi, Antonino Giulio Giannone, Stefania Grimaudo, Giada Sebastiani, Antonio Craxì, C. La Mantia, Grazia Pennisi, Marco Enea, A.L. Fracanzani, Vincent Wai-Sun Wong, V. Di Marco, G. Lupo, C. Cammà, Daniela Cabibi, Manuel Romero-Gómez, Federica Vernuccio, Annalisa Berzigotti, S. Petta, and F. Di Salvo
Subjects: medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Nonalcoholic fatty liver disease, Gastroenterology, medicine, In patient, business, medicine.disease
Published: 2021
Full Text: View/download PDF

2. Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement

Author: V. de Ledinghen, R. Myers, Thomas Karlas, David Petroff, H. W. Lee, Keiichi Masaki, Michel Beaugrand, Jean-Baptiste Hiriart, Maneesh Kumar, P. Bedossa, Y. Q. Mi, Sanjiv Mahadeva, Giovanna Ferraioli, Jian-Gao Fan, Wah-Kheong Chan, Magali Sasso, Volker Keim, Pam Crotty, Monica Lupsor-Platon, Carlo Filice, Radu Badea, Shiv Kumar Sarin, Patrick Marcellin, Johannes Wiegand, Kazuaki Chayama, Grace Lai-Hung Wong, Feng Shen, Mireen Friedrich-Rust, A.C. Cardoso, Kwang Hyub Han, Vincent Wai-Sun Wong, and Jörg Bojunga
Subjects: 0301 basic medicine, medicine.medical_specialty, Cirrhosis, Hepatology, medicine.diagnostic_test, business.industry, Fatty liver, Gastroenterology, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Fibrosis, Positive predicative value, Meta-analysis, Internal medicine, medicine, 030211 gastroenterology & hepatology, Pharmacology (medical), Elastography, Steatosis, Transient elastography, business
Abstract: Background Liver fibrosis is often accompanied by steatosis, particularly in patients with non-alcoholic fatty liver disease (NAFLD), and its non-invasive characterisation is of utmost importance. Vibration-controlled transient elastography is the non-invasive method of choice; however, recent research suggests that steatosis may influence its diagnostic performance. Controlled Attenuation Parameter (CAP) added to transient elastography enables simultaneous assessment of steatosis and fibrosis. Aim To determine how to use CAP in interpreting liver stiffness measurements. Methods This is a secondary analysis of data from an individual patient data meta-analysis on CAP. The main exclusion criteria for the current analysis were unknown aetiology, unreliable elastography measurement and data already used for the same research question. Aetiology-specific liver stiffness measurement cut-offs were determined and used to estimate positive and negative predictive values (PPV/NPV) with logistic regression as functions of CAP. Results Two thousand and fifty eight patients fulfilled the inclusion criteria (37% women, 18% NAFLD/NASH, 42% HBV, 40% HCV, 51% significant fibrosis ≥ F2). Youden optimised cut-offs were only sufficient for ruling out cirrhosis (NPV of 98%). With sensitivity and specificity-optimised cut-offs, NPV for ruling out significant fibrosis was moderate (70%) and could be improved slightly through consideration of CAP. PPV for significant fibrosis and cirrhosis were 68% and 55% respectively, despite specificity-optimised cut-offs for cirrhosis. Conclusions Liver stiffness measurement values below aetiology-specific cut-offs are very useful for ruling out cirrhosis, and to a lesser extent for ruling out significant fibrosis. In the case of the latter, Controlled Attenuation Parameter can improve interpretation slightly. Even if cut-offs are very high, liver stiffness measurements are not very reliable for ruling in fibrosis or cirrhosis.
Published: 2018
Full Text: View/download PDF

3. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD

Author: Salvatore Petta, Jean-Baptiste Hiriart, Wassil Merrouche, Antonio Craxì, J. Vergniol, Fabio Marra, Anthony W.H. Chan, Vincent Wai-Sun Wong, V. de Ledinghen, Umberto Arena, Brigitte Le-Bail, Grace Lai-Hung Wong, Calogero Cammà, Hung Chan, V. Di Marco, Petta, S., Wong, V., Camma', C., Hiriart, J., Wong, G., Vergniol, J., Chan, A., DI MARCO, V., Merrouche, W., Chan, H., Marra, F., Le-Bail, B., Arena, U., Craxi, A., and de Ledinghen, V.
Subjects: Adult, Liver Cirrhosis, Male, medicine.medical_specialty, Liver fibrosis, Diagnostic accuracy, Sensitivity and Specificity, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, Liver stiffness, Fibrosis, Internal medicine, Histological diagnosis, Nonalcoholic fatty liver disease, medicine, Humans, Pharmacology (medical), In patient, Aged, Hepatology, business.industry, Non invasive, Middle Aged, medicine.disease, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, business, Algorithms
Abstract: SummaryBackground The accuracy of available non-invasive tools for staging severe fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) is still limited. Aim To assess the diagnostic performance of paired or serial combination of non-invasive tools in NAFLD patients. Methods We analysed data from 741 patients with a histological diagnosis of NAFLD. The GGT/PLT, APRI, AST/ALT, BARD, FIB-4, and NAFLD Fibrosis Score (NFS) scores were calculated according to published algorithms. Liver stiffness measurement (LSM) was performed by FibroScan. Results LSM, NFS and FIB-4 were the best non-invasive tools for staging F3-F4 fibrosis (AUC 0.863, 0.774, and 0.792, respectively), with LSM having the highest sensitivity (90%), and the highest NPV (94%), and NFS and FIB-4 the highest specificity (97% and 93%, respectively), and the highest PPV (73% and 79%, respectively). The paired combination of LSM or NFS with FIB-4 strongly reduced the likelihood of wrongly classified patients (ranging from 2.7% to 2.6%), at the price of a high uncertainty area (ranging from 54.1% to 58.2%), and of a low overall accuracy (ranging from 43% to 39.1%). The serial combination with the second test used in patients in the grey area of the first test and in those with high LSM values (>9.6 KPa) or low NFS or FIB-4 values (
Published: 2017
Full Text: View/download PDF

4. The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI

Author: Annalisa Berzigotti, Paul Calès, Federico Ravaioli, V. de Ledinghen, Nathalie Ganne-Carrié, Oana Farcau, S. Petta, C. Bureau, P. Nahon, Davide Festi, H. Stefanescu, and Arthur Berger
Subjects: medicine.medical_specialty, Esophageal varices, Hepatology, business.industry, Internal medicine, Gastroenterology, Etiology, Medicine, business, medicine.disease
Published: 2020
Full Text: View/download PDF

5. Personalized platelets/liver stiffness ratio improves and secures the screening of esophageal varices needing treatment

Author: Federico Ravaioli, F. Buisson, Berger, V. de Ledinghen, H. Stefanescu, Cluj, Angers, Paul Calès, Nathalie Ganne-Carrié, Toulouse, Annalisa Berzigotti, S. Petta, P. Nahon, Davide Festi, Bologna, Bordeaux, C. Bureau, Bern, Bondy, and Oana Farcau
Subjects: medicine.medical_specialty, Esophageal varices, Hepatology, Liver stiffness, business.industry, Internal medicine, Gastroenterology, medicine, Platelet, business, medicine.disease
Published: 2020
Full Text: View/download PDF

6. Safety of sofosbuvir-based regimens after liver transplantation longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study

Author: Rodolphe Anty, Alpha Diallo, Vincent Leroy, L. D’Alteroche, Jean Charles Duclos-Vallée, Claire Fougerou-Leurent, Christophe Duvoux, Vincent L.M. Esnault, P. Perré, François Habersetzer, Audrey Coilly, Aurelie Veislinger, Nassim Kamar, V. Di Martino, Emilie Rossignol, Valérie Canva, Maryline Debette-Gratien, Carole Cagnot, François Durand, Didier Samuel, Clémence M. Canivet, Danielle Botta-Fridlund, H. Montialoux, V. de Ledinghen, Christine Silvain, Camille Besch, Jérôme Dumortier, Albert Tran, Guillaume Favre, Pauline Houssel-Debry, Georges Philippe Pageaux, S. Radenne, H. Danjou, Sébastien Dharancy, Fabio Conti, Pascal Lebray, Armando Abergel, Christophe Moreno, Centre Hospitalier Universitaire de Nice (CHU Nice), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Laboratoire de PhysioMédecine Moléculaire (LP2M), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Grenoble, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Toulouse [Toulouse], Hôpital Claude Huriez [Lille], CHU Lille, Hôpital Edouard Herriot [CHU - HCL], Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Strasbourg, CHU Marseille, CHU Rouen, Normandie Université (NU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Interactions Virus-Hôte et Maladies Hépatiques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Virologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, CHU Limoges, ANRS France Recherche Nord & sud Sida-hiv hépatites, Hôpital Lapeyronie [Montpellier] (CHU), Université Nice Sophia Antipolis (1965 - 2019) (UNS), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
Subjects: medicine.medical_specialty, Sofosbuvir, Hepatitis C virus, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Urology, Renal function, Hepacivirus, 030230 surgery, Liver transplantation, medicine.disease_cause, Kidney, Cohort Studies, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Recurrence, Ribavirin, Medicine, Humans, Pharmacology (medical), Longitudinal Studies, Prospective Studies, Renal Insufficiency, Chronic, Aged, Creatinine, Hepatology, business.industry, Gastroenterology, Middle Aged, Hepatitis C, 3. Good health, Liver Transplantation, medicine.anatomical_structure, chemistry, Cohort, 030211 gastroenterology & hepatology, Female, business, medicine.drug, Glomerular Filtration Rate
Abstract: International audience; Background In liver transplant recipients with hepatitis C virus recurrence, there is concern about renal safety of sofosbuvir-based regimens. Changes in serum creatinine or in the estimated glomerular filtration rate (eGFR) under treatment are used to look for possible renal toxicity. However, serum creatinine and eGFR are highly variable. Aim To analyse renal function trajectory with numerous assays of serum creatinine over a long period of time. Methods In a multicentre cohort of 139 patients, the eGFR was obtained from serum creatinine using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation. Slopes of eGFR were defined as a change in eGFR during a period divided by time. Pre-treatment, on-treatment and post-treatment periods were 9 months, 3-9 months and 4.5 months. Interactions between eGFR slopes and the pre-treatment eGFR, use of ribavirin or mycophenolate mofetil, and stage of fibrosis were addressed. On-treatment eGFR slopes were separated in tertiles. Pre- and post-treatment eGFR slopes were compared globally and according to tertiles. Results The post-treatment eGFR slope was significantly better than pre-treatment eGFR slope (+0.18 (IQR -0.76 to +1.32) vs -0.11 (IQR -1.01 to +0.73) mL/min/1.73 m(2)/month, P=0.03) independently of the pre-treatment eGFR (P=0.99), ribavirin administration (P=0.26), mycophenolate mofetil administration (P=0.51) and stage of fibrosis (F3 and F4 vs lower stages, P=0.18; F4 vs lower stages, P=0.08; F4 Child-Pugh B and C vs lower stages, P=0.38). Tertiles of on-treatment eGFR slopes were -1.71 (IQR -2.54 to -1.48), -0.78 (IQR -1.03 to -0.36) and +0.75 (IQR +0.28 to +1.47) mL/min/1.73 m(2)/month. Pre- and post-treatment eGFR slopes were not significantly different according to tertiles (respectively, P=0.34, 0.08, 0.73). Conclusion The eGFR varies during treatment and gives a confusing picture of the renal safety of sofosbuvir-based regimens. In contrast, longitudinal assessment of the eGFR shows a rising trajectory over longer time, meaning that these therapies are safe for the kidneys in our cohort of liver transplant recipients.
Published: 2018
Full Text: View/download PDF

7. Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients after Liver Transplantation: Results from the ANRS CO23 CUPILT Study

Author: Didier Samuel, Audrey Coilly, Jérôme Dumortier, Vincent Leroy, Danielle Botta-Fridlund, Anne-Marie Taburet, P. Perré, A. Rohel, Aurelie Veislinger, Emilie Rossignol, Teresa Antonini, Valérie Canva, Pauline Houssel-Debry, Jean Charles Duclos-Vallée, Sylvie Radenne, Georges Philippe Pageaux, Alpha Diallo, Nassim Kamar, Claire Fougerou-Leurent, François Durand, V. de Ledinghen, Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Dynamique des systèmes d'adhérence et différenciation (DySAD), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), CHU Marseille, Centre de recherche biomédicale Bichat-Beaujon (CRB3), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Foie, métabolismes et cancer, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Services de Maladies de l'Appareil Digestif, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France, Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille, CHU Bordeaux [Bordeaux], ANRS France Recherche Nord & sud Sida-hiv hépatites, Immunologie des Maladies Virales et Autoimmunes (IMVA - U1184), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Lapeyronie [Montpellier] (CHU), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Ledipasvir, Male, medicine.medical_specialty, Daclatasvir, Sofosbuvir, medicine.medical_treatment, Hepatitis C virus, [SDV]Life Sciences [q-bio], HIV Infections, Liver transplantation, medicine.disease_cause, Gastroenterology, Antiviral Agents, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Humans, 030212 general & internal medicine, Transplantation, business.industry, Coinfection, Ribavirin, virus diseases, Hepatitis C, Middle Aged, medicine.disease, 3. Good health, Liver Transplantation, chemistry, Liver, 030211 gastroenterology & hepatology, Female, business, Viral load, medicine.drug
Abstract: Background A recurrence of hepatitis C virus (HCV) after liver transplantation affects survival in human immunodeficiency virus (HIV)/HCV coinfected patients. This study assessed the efficacy and safety of sofosbuvir (SOF)-based regimens in HIV/HCV coinfected patients after liver transplantation. Methods Twenty-nine HIV/HCV coinfected transplanted patients receiving tacrolimus-, cyclosporine-, or everolimus-based immunosuppressive therapy were enrolled in the Compassionate Use of Protease Inhibitors in Viral C Liver Transplantation cohort. Their antiviral treatment combined SOF, daclatasvir with or without ribavirin (n = 10/n = 6), or SOF, ledipasvir with or without ribavirin (n = 2/n = 11). Results The median delay between liver transplantation and treatment initiation was 37.5 months (interquartile range [IQR], 14.4-99.2). The breakdown of HCV genotypes was G1, 22 patients (75.9%); G3, 3 patients (10.3%); and G4, 4 patients (13.8%). The treatment indications were HCV recurrence (≥ F1 n = 23) or fibrosing cholestatic hepatitis (n = 6). Before starting SOF, the HCV viral load and CD4 count were 6.7 log 10 IU/mL (IQR, 5.9-7.2) and 342 cells/mm 3 (IQR, 172-483), respectively. At week 4, the HCV viral load was less than 15 IU/mL in 12 (42.9%) patients. The overall sustained virological response 12 was 96.6%. No significant drug-drug interactions were observed. Conclusions SOF-based treatment regimens produced excellent results in HIV/HCV coinfected patients after liver transplantation, suggesting an important change in their prognosis. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Published: 2018
Full Text: View/download PDF

8. P.04.19 FROM GUIDELINES TO UNIFORM PAN-HEALTHCARE PROFESSIONAL PRACTICE: DEVELOPMENT OF AN INTERNATIONAL CONSENSUS CARE PATHWAY FOR THE DIAGNOSIS AND MANAGEMENT OF PRIMARY BILIARY CHOLANGITIS

Author: Guilherme Macedo, Olivier Chazouillères, Helena Cortez-Pinto, F. Adekunle, V. de Ledinghen, Gideon M. Hirschfield, and Marco Carbone
Subjects: medicine.medical_specialty, Hepatology, Health professionals, business.industry, Family medicine, Gastroenterology, medicine, Care pathway, business
Published: 2019
Full Text: View/download PDF

9. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences

Author: Stanislas Pol, Pierre Nahon, Fabrice Carrat, Christine Larsen, Fabien Zoulim, Hélène Fontaine, M. Bourlière, Georges Haour, French Anrs Co Hepather cohort, Dominique Larrey, Céline Dorival, Linda Wittkop, J-M Pawlostky, Jacqueline Capeau, Francesco Negro, J-P Zarski, V. de Ledinghen, Philippe Mathurin, Patrice Cacoub, G-P Pageaux, Yazdan Yazdanpanah, Ventzislava Petrov-Sanchez, Patrizia Carrieri, Patrick Marcellin, Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidémiologie, Systèmes d'Information, Modélisation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), ANRS France Recherche Nord & sud Sida-hiv hépatites, Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Université Pierre et Marie Curie - Paris 6 (UPMC), Sorbonne Universités (COMUE), Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Santé publique France - French National Public Health Agency [Saint-Maurice, France], Service d’Hépatologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18) (Inserm U955), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Génomique Fonctionnelle des Tumeurs Solides (U1162), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Bordeaux Research In Translational Oncology [Bordeaux] (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille], Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Geneva University Hospital (HUG), Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Departement Hospitalo- Universitaire - Inflammation, Immunopathologie, Biothérapie [Paris] (DHU - I2B), and Université Pierre et Marie Curie - Paris 6 (UPMC)-CHU Pitié-Salpêtrière [AP-HP]
Subjects: 0301 basic medicine, Male, Liver Cirrhosis, Cirrhosis, viruses, Coinfection/virology, [SDV]Life Sciences [q-bio], medicine.disease_cause, Gastroenterology, Cohort Studies, 0302 clinical medicine, Fibrosis, Medicine, Pharmacology (medical), ddc:616, biology, Coinfection, virus diseases, Middle Aged, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, Hepatitis B, Hepatitis C, 3. Good health, 030211 gastroenterology & hepatology, Female, Antibody, Cohort study, Adult, medicine.medical_specialty, Hepatitis B/epidemiology/pathology, Hepatitis C virus, Hepatitis b surface antigen, 03 medical and health sciences, Internal medicine, Humans, Aged, Hepatitis B virus, Hepatology, business.industry, Liver Cirrhosis/epidemiology/pathology, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Hepatitis C/epidemiology/pathology, Hepatitis C Antibodies, medicine.disease, Virology, digestive system diseases, ddc:616.8, 030104 developmental biology, biology.protein, business
Abstract: International audience; BACKGROUND: Hepatitis B virus (HBV)/hepatitis C virus (HCV) confection has been rarely studied in nonasian series. AIM: To compare the characteristics of HBV/HCV coinfected patients to those of HBV- or HCV-monoinfected patients in the ANRS CO22 HEPATHER cohort study. PATIENTS AND METHODS: Of the 20 936 included patients, 95 had HBV/HCV coinfection (hepatitis B surface antigen, anti-HCV antibody and HCV RNA positive) and were matched with 375 HBV- and 380 HCV-monoinfected patients on age, gender and time since HBV or HCV diagnosis. RESULTS: F3-F4 fibrosis was more frequent in coinfected patients (58%) than in HBV- (32%, P \textless .0001), but similar in HCV-monoinfected patients (52%, P = .3142). Decompensated cirrhosis was more frequent in coinfected patients (11%) than in HBV- (2%, P = .0002) or HCV- (4%, P = .0275) monoinfected patients. Past excessive alcohol use was more frequent in coinfected patients (26%) than in HBV (12%, P = .0011), but similar in HCV monoinfected patients (32%, P = .2868). Coinfected patients had a higher proportion with arterial hypertension (42%) than HBV- (26%) or HCV-monoinfected patients (25%) (P \textless .003). Multivariable analysis confirmed the association between F3-F4 fibrosis and HCV infection in HBV-infected patients (OR = 3.84, 95% CI 1.99-7.43) and the association between decompensated cirrhosis and coinfection in HBV infected (OR = 5.58, 95% CI 1.42-22.0) or HCV infected patients (OR = 3.02, 95% CI 1.22-7.44). CONCLUSIONS: HCV coinfection harmfully affects liver fibrosis in HBV patients, while decompensated cirrhosis is increased in coinfected patients compared with HBV- or HCV-monoinfected patients. HCV treatment is as safe and effective in coinfected as monoinfected patients and should be considered following the same rules as HCV monoinfected patients.
Published: 2017
Full Text: View/download PDF

10. Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination?

Author: V. de Ledinghen, I. Hubert, Paul Calès, Frédéric Oberti, Christophe Aubé, Jérôme Boursier, Jérôme Lebigot, Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Centre d'investigation de la fibrose hépatique [CHU de Bordeaux] (Hôpital Haut-Lévêque ), and Hôpital Haut-Lévêque [CHU de Bordeaux]
Subjects: Adult, Liver Cirrhosis, Male, medicine.medical_specialty, Concordance, [SDV]Life Sciences [q-bio], Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Fibrosis, Internal medicine, Medicine, Blood test, Humans, Pharmacology (medical), Chronic, Aged, Hematologic Tests, Hepatology, medicine.diagnostic_test, business.industry, Hepatitis C, Middle Aged, medicine.disease, 3. Good health, Surgery, Test (assessment), 030220 oncology & carcinogenesis, Elasticity Imaging Techniques, 030211 gastroenterology & hepatology, Female, Elastography, business, Transient elastography, Viral hepatitis
Abstract: International audience; BACKGROUND: In chronic hepatitis C, the European Association for the Study of the Liver and the Asociacion Latinoamericana para el Estudio del Higado recommend performing transient elastography plus a blood test to diagnose significant fibrosis; test concordance confirms the diagnosis.AIM: To validate this rule and improve it by combining a blood test, FibroMeter (virus second generation, Echosens, Paris, France) and transient elastography (constitutive tests) into a single combined test, as suggested by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.METHODS: A total of 1199 patients were included in an exploratory set (HCV, n = 679) or in two validation sets (HCV ± HIV, HBV, n = 520). Accuracy was mainly evaluated by correct diagnosis rate for severe fibrosis (pathological Metavir F ≥ 3, primary outcome) by classical test scores or a fibrosis classification, reflecting Metavir staging, as a function of test concordance.RESULTS: Score accuracy: there were no significant differences between the blood test (75.7%), elastography (79.1%) and the combined test (79.4%) (P = 0.066); the score accuracy of each test was significantly (P < 0.001) decreased in discordant vs. concordant tests. Classification accuracy: combined test accuracy (91.7%) was significantly (P < 0.001) increased vs. the blood test (84.1%) and elastography (88.2%); accuracy of each constitutive test was significantly (P < 0.001) decreased in discordant vs. concordant tests but not with combined test: 89.0 vs. 92.7% (P = 0.118). Multivariate analysis for accuracy showed an interaction between concordance and fibrosis level: in the 1% of patients with full classification discordance and severe fibrosis, non-invasive tests were unreliable. The advantage of combined test classification was confirmed in the validation sets.CONCLUSIONS: The concordance recommendation is validated. A combined test, expressed in classification instead of score, improves this rule and validates the recommendation of a combined test, avoiding 99% of biopsies, and offering precise staging.
Published: 2017
Full Text: View/download PDF

11. HCV: Fibrosis Progression

Author: V. De Ledinghen and Julien Vergniol
Subjects: medicine.medical_specialty, Pathology, Cirrhosis, Hepatology, medicine.diagnostic_test, business.industry, Disease, Hepatitis C, medicine.disease, Gastroenterology, Virological response, Fibrosis, Virology, Liver biopsy, Internal medicine, medicine, In patient, business
Abstract: Chronic hepatitis C is a frequent disease worldwide and is responsible for a high rate of advanced fibrosis and a significant risk of liver complications and death in patients. Liver fibrosis progression illustrates the aggravation of the disease and the increasing risks over time. Many tools are available to diagnose fibrosis progression, and recent results display how in 2014 liver biopsy is avoidable for patient monitoring and prognosis prediction. Many host and viral factors are associated with fibrosis progression, and more data are now available on the impact of antiviral treatment and sustained virological response on liver fibrosis, whatever its severity, and long-term patient’s outcome.
Published: 2014
Full Text: View/download PDF

12. Noninvasvie prediction of oesophageal varics by liver stiffness measurement and platelet values in patients with liver cirrhosis due to nonalcoholic fatty liver disease: A multicenter cross-sectional study

Author: Vincenza Calvaruso, Marco Barbara, W. Sun, A.L. Fracanzani, Giada Sebastiani, M.G. Rumi, V. Di Marco, Quentin M. Anstee, Annalisa Berzigotti, V. de Ledinghen, S. Petta, Mauro Viganò, Rossana Lombardi, Fabio Marra, Vincent Wai-Sun Wong, C. Cammà, Antonio Craxì, and Elisabetta Bugianesi
Subjects: medicine.medical_specialty, Cirrhosis, Hepatology, Cross-sectional study, business.industry, medicine.disease, Gastroenterology, Liver stiffness, Internal medicine, Nonalcoholic fatty liver disease, medicine, Platelet, In patient, business
Published: 2018
Full Text: View/download PDF

13. Estimated risk reduction of mortality and transplantation with bezafibrate in patients with PBC and inadequate response to UDCA: application of the UK-PBC and Global PBC risk scores to the BEZURSO trial

Author: R. Olivier, Jérôme Boursier, Fabien Zoulim, Odile Goria, M.D. Gratien, Dominique Larrey, Armando Abergel, Tabassome Simon, P. Mathurin, Alexandra Heurgué-Berlot, Eric Nguyen-Khac, Olivier Chazouillères, L.G. Antonia, F.-H. Admane, N. Gisèle, Christophe Corpechot, Jean-Pierre Bronowicki, Alexandra Rousseau, Anne Minello Franza, C. Silvain, François Habersetzer, O.-H. Isabelle, P. Pascal, R.E. Poupon, V. de Ledinghen, Gaouar Farid, and Jean-Pierre Zarski
Subjects: Transplantation, Reduction (complexity), medicine.medical_specialty, Bezafibrate, Hepatology, business.industry, Internal medicine, medicine, In patient, business, Gastroenterology, medicine.drug
Published: 2018
Full Text: View/download PDF

14. Noninvasive prediction of esophageal varices by liver stiffness measurement and platelet values in patients with liver cirrhosis due to nonalcoholic fatty liver disease: A multicenter cross-sectional study

Author: V. de Ledinghen, C. Cammà, Fabio Marra, A.L. Fracanzani, Elisabetta Bugianesi, Rossana Lombardi, Antonio Craxì, Mauro Viganò, Vincent Wai-Sun Wong, Marco Barbara, S. Petta, Quentin M. Anstee, Annalisa Berzigotti, Vincenza Calvaruso, M.G. Rumi, V. Di Marco, and Giada Sebastiani
Subjects: medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Cross-sectional study, Gastroenterology, medicine.disease, Esophageal varices, Liver stiffness, Internal medicine, Nonalcoholic fatty liver disease, medicine, Platelet, In patient, business
Published: 2018
Full Text: View/download PDF

15. PGI27 THE BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN THE EU5 COUNTRIES

Author: V. Ratziu, Javier Crespo, Rachel Elliott, S. Cure, Salvatore Petta, Salvador Augustin, Jörn M. Schattenberg, Lawrence Serfaty, E. Stirzaker, Elisabetta Bugianesi, Vincenzo Atella, Jérôme Boursier, Manuel Romero-Gómez, P N Newsome, S. Vasudevan, J. Mestre-Ferrandiz, S. Hartmanis, Emmanuel Tsochatzis, A. Torbica, Heike Bantel, Laurent Castera, Lefteris Floros, Ali Canbay, A. Morgan, A. Trylesinski, Lynne Pezzullo, Alessio Aghemo, Vincent Leroy, F. Fricke, V. de Ledinghen, Stephen D. Ryder, and C. Le Pen
Subjects: medicine.medical_specialty, business.industry, Health Policy, Internal medicine, Public Health, Environmental and Occupational Health, medicine, Non alcoholic, Steatohepatitis, medicine.disease, business, Gastroenterology
Published: 2019
Full Text: View/download PDF

16. Transient elsatography, a key tool in the screening of complications in patients with Fontan circulation

Author: V. de Ledinghen, M. Mostefa-Kara, Xavier Iriart, Jean-Benoit Thambo, Jean Baptiste Hiriart, Zakaria Jalal, J. Chabaneix-Thomas, J. Vergnol, J. Foucher, and Pierre-Emmanuel Séguéla
Subjects: medicine.medical_specialty, Cirrhosis, medicine.diagnostic_test, business.industry, Physical examination, medicine.disease, Work-up, Congestive hepatopathy, Internal medicine, Cardiology, medicine, In patient, Cardiology and Cardiovascular Medicine, Complication, Transient elastography, Lead (electronics), business
Abstract: Backgrounds Congestive hepatopathy usually appears and develops slowly after a Fontan operation, often without obvious clinical features, but it may lead to life-threatening complications. Objective We aim to assess the potential usefulness of the liver stiffness (LS) in the longitudinal follow up of Fontan patients. Material and method Patients were prospectively evaluated using clinical examination, laboratory tests, echocardiography and LS using transient elastography (TF). This work up was made annually or in case of clinical complication. Results Forty-six patients (22.1 ± 8,1 years of age and 9.7 ± 6.5 years post-Fontan) were enrolled. Mean time between first and last work up was 3.27 ± 1.9 years. During this period clinical complication occurred in 12/46 (26%) including 6 arrhythmias, 2 cirrhosis, 1 steato-hepatitis, 3 exudative enteropathies and 2 venous-collateral. Mean LS at baseline was 14 ± 7.4 kPa. LS was significantly higher in patient with complications compared to those who were free from any complication (17.2 ± 7.7 vs. 13.8 ± 5.9 kPa, P = 0.019). No significant change in stiffness was also observed with age (P = 0.73), time since Fontan (P = 0.64), presence fenestration (15 ± 6.8 vs. 15.1 ± 6.7 kPa, P = 0.82) or ventricular morphology (15 ± 13.1 vs. 16 ± 14.1 vs. 10.9 ± 11.6 kPa, P = 0.09). Conclusion Fibroscan appears to be a good tool for the non-invasive follow-up of FP. Indeed, a significate elevation of the LS is associated with the occurrence of complications.
Published: 2019
Full Text: View/download PDF

17. Should we keep using Ribavirin to Treat Hepatitis C Recurrence after Liver Transplantation? Results from the CO23 ANRS Cupilt Study

Author: Jean Charles Duclos-Vallée, F. Durand, Valérie Canva, V. Di Martino, Abou Diallo, G.-P. Pageaux, S. Radenne, Claire Fougerou-Leurent, Emilie Rossignol, Aurelie Veislinger, Pauline Houssel-Debry, Rodolphe Anty, H. Danjou, Vincent Leroy, Christophe Duvoux, L. D’Alteroche, C. Silvain, Audrey Coilly, V. de Ledinghen, Camille Besch, Caroline Jezequel, Maryline Debette-Gratien, A. Rohel, François Habersetzer, Nassim Kamar, H. Montialoux, Jérôme Dumortier, Armando Abergel, Christophe Moreno, Fabio Conti, Pascal Lebray, Danielle Botta-Fridlund, P. Perré, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Service d'Hépatologie, Hôpital Henri Mondor, AP-HP, Créteil, France., Hôpital Henri Mondor, Hôpital Paul Brousse, Département d'hépatologie, Hospices Civils de Lyon (HCL), Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Services de Maladies de l'Appareil Digestif, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France, Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille, CHU Pitié-Salpêtrière [AP-HP], Service d'hépato-gastroentérologie, Hôpital de la Conception, AP-HM, Marseille, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Laboratoire Inflammation, Tissus épithéliaux et Cytokines (LITEC), Université de Poitiers, Service de Transplantation, Centre Hospitalier Universitaire de Strasbourg, Centre Hospitalier Universitaire de Strasbourg (CHU de Strasbourg ), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Unité de la recherche fondamentale et clinique sur l' hépatite virale, France Recherche Nord & Sud Asdi-VIH Hépatites, Agence Nationale de Recherche sur le Sida, Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Ribavirin, [SDV]Life Sciences [q-bio], Hepatitis C, 030230 surgery, Liver transplantation, medicine.disease, Gastroenterology, 3. Good health, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Internal medicine, Medicine, 030211 gastroenterology & hepatology, business
Abstract: International audience; EASL International Liver Congress, APR 13-17, 2016, Barcelona, SPAIN
Published: 2016
Full Text: View/download PDF

18. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Author: Dean W. Hum, T. Foster, Tarik Asselah, Mario Angelico, Antonio Craxì, Lawrence Serfaty, J. Gournay, Albert Geerts, Philippe Lehert, Javier Crespo, M. A. Huang, M. Voiculescu, Sven Francque, G. Abouda, Ulrich Beuers, David Cassiman, Manuel Romero-Gómez, Frederik Nevens, Philippe Mathurin, V. Clark, Sanjaya K. Satapathy, Dominique Larrey, Christophe Moreno, Arun J. Sanyal, Guruprasad P. Aithal, Pierre Bedossa, Terry Box, Guillermo E. Umpierrez, L. Preotescu, J. Gallegos-Orozco, Jean Henrion, Eric Nguyen-Khac, Steve Caldwell, J. L. Callera, M. Bourliere, Ulrich Spengler, R. K. Reddy, Bart Staels, Gyongyi Szabo, Fred Poordad, Muhammad Y. Sheikh, M. W. Moehlen, Raúl J. Andrade, Vlad Ratziu, V. de Ledinghen, Stephen A. Harrison, Juan Caballería, Manal F. Abdelmalek, Velimir A. Luketic, S. Megnien, A. Roudot, Jérôme Boursier, A. Tran, Aftab Ala, N. Shores, Rémy Hanf, Peter R. Galle, Quentin M. Anstee, M. Maynard-Muet, C. Chang, Liana Gheorghe, Joost P.H. Drenth, Stuart C. Gordon, Elisabetta Bugianesi, S. Parekh, Silvia Fargion, Kiran Bambha, John M. Vierling, Paul J. Pockros, Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Antwerp University Hospital [Edegem] (UZA), Service d'anatomie pathologique [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Faculty of Medicine, University of Melbourne, Faculty of Economics, UcLouvain - Louvain School of Management - Campus Mons Management department, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unit for The Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Anenida de Bellavista s/n, Sevilla 41014, Spain, Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Radboud University Medical Center [Nijmegen], Newcastle University [Newcastle], Genfit, Entreprise biopharmaceutique GENFIT Loos, Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lille, European Genomic Institute for Diabetes - FR 3508 (EGID), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Virginia Commonwealth University (VCU), Ratziu V., Harrison S.A., Francque S., Bedossa P., Lehert P., Serfaty L., Romero-Gomez M., Boursier J., Abdelmalek M., Caldwell S., Drenth J., Anstee Q.M., Hum D., Hanf R., Roudot A., Megnien S., Staels B., Sanyal A., Mathurin P., Gournay J., Nguyen-Khac E., De Ledinghen V., Larrey D., Tran A., Bourliere M., Maynard-Muet M., Asselah T., Henrion J., Nevens F., Cassiman D., Geerts A., Moreno C., Beuers U.H., Galle P.R., Spengler U., Bugianesi E., Craxi A., Angelico M., Fargion S., Voiculescu M., Gheorghe L., Preotescu L., Caballeria J., Andrade R.J., Crespo J., Callera J.L., Ala A., Aithal G., Abouda G., Luketic V., Huang M.A., Gordon S., Pockros P., Poordad F., Shores N., Moehlen M.W., Bambha K., Clark V., Satapathy S., Parekh S., Reddy R.K., Sheikh M.Y., Szabo G., Vierling J., Foster T., Umpierrez G., Chang C., Box T., Gallegos-Orozco J., CHU Tenon [AP-HP], Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 (EGID), and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)
Subjects: 0301 basic medicine, Liver Cirrhosis, Male, Time Factors, Intention to Treat Analysi, [SDV]Life Sciences [q-bio], Biopsy, PLACEBO-CONTROLLED TRIAL, THERAPY, Gastroenterology, Severity of Illness Index, Chalcone, 0302 clinical medicine, Chalcones, Non-alcoholic Fatty Liver Disease, Gastrointestinal Agent, Nonalcoholic fatty liver disease, Propionate, Medicine and Health Sciences, Odds Ratio, Medicine, Glucose homeostasis, VITAMIN-E, education.field_of_study, Gastrointestinal agent, Fatty liver, Remission Induction, Middle Aged, 3. Good health, Intention to Treat Analysis, PPARD, Europe, Treatment Outcome, Liver, ACID, PIOGLITAZONE, 030211 gastroenterology & hepatology, Female, PPARA, Human, Signal Transduction, Adult, CLINICAL-OUTCOMES, medicine.medical_specialty, Logistic Model, Time Factor, Liver Cirrhosi, Population, fatty liver, NAFLD, Biomarkers, Double-Blind Method, Gastrointestinal Agents, Humans, Logistic Models, PPAR alpha, PPAR gamma, Propionates, United States, Placebo, 03 medical and health sciences, Internal medicine, education, FATTY LIVER-DISEASE, Hepatology, business.industry, Biomarker, AMERICAN ASSOCIATION, Odds ratio, medicine.disease, Confidence interval, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], 030104 developmental biology, Endocrinology, Human medicine, business
Abstract: International audience; BACKGROUND & AIMS: Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).METHODS: Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n= 93), elafibranor 120 mg (n= 91), or placebo (n= 92) each day for 52 weeks at sites in Europe and the United States. Clinical and laboratory evaluations were performed every 2 months during this 1-year period. Liver biopsies were then collected and patients were assessed 3 months later. The primary outcome was resolution of NASH without fibrosis worsening, using protocol-defined and modified definitions. Data from the groups given the different doses of elafibranor were compared with those from the placebo group using step-down logistic regression, adjusting for baseline nonalcoholic fatty liver disease activity score.RESULTS: In intention-to-treat analysis, there was no significant difference between the elafibranor and placebo groups in the protocol-defined primary outcome. However, NASH resolved without fibrosis worsening in a higher proportion of patients in the 120-mg elafibranor group vs the placebo group (19% vs 12%; odds ratio= 2.31; 95% confidence interval: 1.02-5.24; P= .045), based on a post-hoc analysis for the modified definition. In post-hoc analyses of patients with nonalcoholic fatty liver disease activity score ≥4 (n= 234), elafibranor 120 mg resolved NASH in larger proportions of patients than placebo based on the protocol definition (20% vs 11%; odds ratio= 3.16; 95% confidence interval: 1.22-8.13; P= .018) and the modified definitions (19% vs 9%; odds ratio= 3.52; 95% confidence interval: 1.32-9.40; P= .013). Patients with NASH resolution after receiving elafibranor 120 mg had reduced liver fibrosis stages compared with those without NASH resolution (mean reduction of 0.65 ± 0.61 in responders for the primary outcome vs an increase of 0.10 ± 0.98 in nonresponders; P < .001). Liver enzymes, lipids, glucose profiles, and markers of systemic inflammation were significantly reduced in the elafibranor 120-mg group vs the placebo group. Elafibranor was welltolerated and did not cause weight gain or cardiac events, but did produce a mild, reversible increase in serum creatinine (effect size vs placebo: increase of 4.31 ± 1.19 μmol/L; P < .001).CONCLUSIONS: A post-hoc analysis of data from trial of patients with NASH showed that elafibranor (120 mg/d for 1 year) resolved NASH without fibrosis worsening, based on a modified definition, in the intention-to-treat analysis and in patients with moderate or severe NASH. However, the predefined end point was not met in the intention to treat population. Elafibranor was well tolerated and improved patients' cardiometabolic risk profile. ClinicalTrials.gov number: NCT01694849.
Published: 2016
Full Text: View/download PDF

19. How to combine blood test and elastography to stage liver fibrosis in chronic hepatitis C?

Author: I. Hubert, Jérôme Boursier, V. de Ledinghen, Paul Calès, and Frédéric Oberti
Subjects: medicine.medical_specialty, Hepatology, medicine.diagnostic_test, Chronic hepatitis, business.industry, Liver fibrosis, Internal medicine, medicine, Blood test, Elastography, Stage (cooking), business, Gastroenterology
Published: 2017
Full Text: View/download PDF

20. Reliability criteria for the diagnosis of fatty liver using controlled attenuation parameter by transient elastography – A multicentre study of 754 patients

Author: Vincent Wai-Sun Wong, Anthony W.H. Chan, C. Cammà, Hung Chan, J. Vergniol, V. Di Marco, S. Petta, V. de Ledinghen, Jean-Baptiste Hiriart, U. Arena, Fabio Marra, B. Le Bail, Grace Lai-Hung Wong, Antonio Craxì, and Wassil Merrouche
Subjects: medicine.medical_specialty, Hepatology, business.industry, Attenuation, Fatty liver, medicine, Radiology, medicine.disease, Transient elastography, business, Reliability (statistics)
Published: 2017
Full Text: View/download PDF

21. FibroScan-based score to identify patients with non-alcoholic steatohepatitis: development in a multi-centric British cohort and validation in a large American cohort

Author: P N Newsome, Emmanuel Tsochatzis, Véronique Miette, Katherine M. Cebe, Angelo H. Paredes, Magali Sasso, Peter J Eddowes, V. de Ledinghen, D. Sherridan, Michael Allison, Quentin M. Anstee, Céline Fournier, Stephen A. Harrison, Katharine Roberts, Valérie Paradis, Jeremy F. L. Cobbold, P. Bedossa, and Indra Neil Guha
Subjects: medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Cohort, Medicine, Retrospective cohort study, Non alcoholic, Steatohepatitis, business, medicine.disease
Published: 2017
Full Text: View/download PDF

22. The combination of Fibroscan with blood markers in the fibrometerVCTE significantly reduces the use of liver biopsy for the assessment of advanced fibrosis in non-alcoholic fatty liver disease

Author: Maude Charbonnier, Juliette Foucher, B. Le Bail, M.C. Rousselet, Sandrine Bertrais, Paul Calès, Sophie Michalak, Frédéric Oberti, Faiza Chermak, Jean-Baptiste Hiriart, Isabelle Fouchard-Hubert, J. Vergniol, V. de Ledinghen, Jérôme Boursier, and Adrien Lannes
Subjects: 0301 basic medicine, medicine.medical_specialty, Pathology, Hepatology, medicine.diagnostic_test, business.industry, Fatty liver, Non alcoholic, Disease, medicine.disease, Gastroenterology, Advanced fibrosis, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Internal medicine, Liver biopsy, Medicine, 030211 gastroenterology & hepatology, Blood markers, business
Published: 2017
Full Text: View/download PDF

23. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C

Author: Véronique Miette, Céline Fournier, Marianne Ziol, R.E. Poupon, Michel Beaugrand, Patrick Marcellin, Jean-Claude Trinchet, Laurent Sandrin, Magali Sasso, Catherine Douvin, Iulia Tengher-Barna, A.C. Cardoso, and V. de Ledinghen
Subjects: medicine.medical_specialty, Hepatology, medicine.diagnostic_test, Receiver operating characteristic, business.industry, Fibrosis stage, Hepatitis C, medicine.disease, Gastroenterology, Infectious Diseases, Liver steatosis, Chronic hepatitis, Fibrosis, Virology, Internal medicine, Liver biopsy, medicine, Steatosis, business
Abstract: SUMMARY. A novel controlled attenuation parameter (CAP) has been developed for Fibroscanto assess liver steatosis, simultaneously with liver stiffness measurement (LSM). We assessed CAP diagnostic accuracy in a large cohort of patients with chronic hepatitis C (CHC) virus. A total of 615 patients with CHC, who underwent both Fibroscanand liver biopsy, were analysed. Fibrosis was graded using METAVIR score. Steatosis was categorized by visual assess- ment as S0: steatosis in
Published: 2011
Full Text: View/download PDF

24. Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study

Author: Frank Zerbib, Edouard Chabrun, D. Laharie, V. de Ledinghen, F. El Hajbi, S. Mesli, M. Capdepont, Sylvie Razaire, and E. Chanteloup
Subjects: Crohn's disease, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Subgroup analysis, medicine.disease, Faecal calprotectin, Infliximab, Regimen, fluids and secretions, Predictive value of tests, Internal medicine, Immunology, medicine, Pharmacology (medical), Calprotectin, Prospective cohort study, business, medicine.drug
Abstract: Aliment Pharmacol Ther 2011; 34: 462–469 Summary Background Faecal calprotectin is a reliable tool for predicting Crohn’s disease (CD) relapse in patients with sustained remission. Prediction of relapse with faecal calprotectin has been less studied in patients with severe CD treated with anti-TNF. Aim To identify an association between faecal calprotectin concentration and CD clinical relapse in patients achieving remission with infliximab (IFX). Methods From February 2007 to October 2008, consecutive patients with refractory luminal CD were prospectively included when they received three IFX infusions (5 mg/kg at weeks 0, 2 and 6) followed by maintenance with an immunomodulator alone. Faecal calprotectin and C-reactive protein (CRP) were measured at entry and at week 14 (w14). Results Sixty-five patients (43W; median age: 30.4 years) were included, and 50 (77%) were in clinical remission off steroids at w14; twenty-three of fifty (46%) experienced CD clinical relapse during the first year of follow-up. Median faecal calprotectin level at w14 was similar in patients with and without CD clinical relapse (200 and 150 μg/g respectively). When considering two suggested faecal calprotectin cut-offs to predict CD relapse, sensitivities and specificities were 61% and 48% for 130 μg/g, respectively, and 43% and 57% for 250 μg/g. Neither faecal calprotectin nor CRP at baseline and at w14 could predict relapse even when CD location subgroup analysis was considered. Conclusion In patients responding to an infliximab induction regimen, faecal calprotectin measurement at w14 cannot predict Crohn’s disease clinical relapse at 1 year.
Published: 2011
Full Text: View/download PDF

25. Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab

Author: V. de Ledinghen, Armel Reffet, Clément Subtil, Edouard Chabrun, M. Capdepont, Geneviève Belleannée, Sylvie Razaire, and D. Laharie
Subjects: musculoskeletal diseases, medicine.medical_specialty, Crohn's disease, Hepatology, medicine.diagnostic_test, business.industry, Gastroenterology, Colonoscopy, Azathioprine, Disease, medicine.disease, Infliximab, Surgery, Dysplasia, Internal medicine, medicine, heterocyclic compounds, Pharmacology (medical), Methotrexate, Young adult, business, medicine.drug
Abstract: Aliment Pharmacol Ther 2011; 33: 714–721 Summary Background Mucosal healing has become a new therapeutic goal in Crohn’s disease and can be achieved with azathioprine (AZA) or biologics. Methotrexate (MTX) is an effective drug for both the induction and maintenance of remission in Crohn’s disease. However, mucosal healing with MTX has been poorly investigated. Aim To assess the mucosal healing rate in patients with Crohn’s disease with clinical response to MTX as compared with AZA or infliximab (IFX). Methods From October 2007 to May 2009, consecutive patients with Crohn’s disease were prospectively enrolled into a single-centre study when they met the following criteria: previous identification of mucosal ulcerations with ileo-colonoscopy, clinical remission within at least 3 months with MTX, AZA or IFX monotherapy, usual indication for colonoscopy in Crohn’s disease (dysplasia/cancer screening, suspected stenosis) excluding assessment for mucosal healing. Mucosal healing was defined as absence of mucosal ulceration in all segments. Results Fifty-one patients with Crohn’s disease (38 female; median age: 42 years) were included: 18 receiving MTX, 18 AZA and 15 IFX. Mucosal healing was achieved in 2/18 (11%) with MTX, in 9/18 (50%) with AZA (P = 0.011 vs. MTX) and in 9/15 (60%) with IFX (P = 0.008 vs. MTX). Conclusion In patients with Crohn’s disease in sustained clinical remission, mucosal healing is less frequently achieved with MTX as compared with AZA or IFX.
Published: 2011
Full Text: View/download PDF

26. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers

Author: Pascale Trimoulet, V. de Ledinghen, Pierre-Henri Bernard, B. Le Bail, Wassil Merrouche, P. Couzigou, Juliette Foucher, and Laurent Castera
Subjects: medicine.medical_specialty, medicine.disease_cause, Gastroenterology, Transaminase, 03 medical and health sciences, 0302 clinical medicine, Fibrosis, Internal medicine, medicine, Pharmacology (medical), Hepatitis B virus, Hepatology, biology, medicine.diagnostic_test, FibroTest, business.industry, Hepatitis B, medicine.disease, 3. Good health, Alanine transaminase, 030220 oncology & carcinogenesis, Liver biopsy, biology.protein, 030211 gastroenterology & hepatology, business, Transient elastography
Abstract: Summary Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally in hepatitis B. Aim To evaluate longitudinally transient elastography (TE) and biomarkers for liver fibrosis assessment and follow-up of hepatitis B virus (HBV) inactive carriers. Methods Three hundred and twenty-nine consecutive HBeAg-negative HBV patients (201 inactive carriers) who underwent TE, Fibrotest and aspartate to platelet ratio index (APRI) the same day were studied. Results TE (median 4.8 vs. 6.8 kPa, P 7.2 kPa) confirmed during follow-up in two with significant fibrosis (F2 and F3) on liver biopsy. Conclusion Non-invasive tools, particularly TE, could be useful, in addition to HBV DNA and transaminase levels, for follow-up of HBV inactive carriers as well as better selection of patients who require a liver biopsy.
Published: 2011
Full Text: View/download PDF

27. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure

Author: Thierry Poynard, Vlad Ratziu, Philippe Halfon, Françoise Imbert-Bismut, Laurent Castera, V. de Ledinghen, Djamila Messous, Patrice Cacoub, M. Bourlière, Dominique Thabut, Mona Munteanu, and Yen Ngo
Subjects: Adult, Male, Pathology, medicine.medical_specialty, Standard of care, Biopsy, Gastroenterology, Chronic hepatitis, Internal medicine, Individual data, medicine, Humans, In patient, Alanine aminotransferase, Receiver operating characteristic, business.industry, Alanine Transaminase, General Medicine, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, Liver, ROC Curve, Meta-analysis, Female, business, Biomarkers, Blood Chemical Analysis
Abstract: ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity validated in patients with chronic hepatitis C (HCV).The aim was to assess the accuracy of AT in comparison with alanine aminotransferase (ALT) the standard of care.Methods used an integrated database of individual data and the new recommended Obuchowski measures. An updated "classical" meta-analysis of AT validation studies was also performed. The main end points were the area under the ROC curves (AUROCs) for the diagnosis of each histological activity grade defined using METAVIR scoring system. To avoid repeated tests and the spectrum effect of activity grades prevalence, the comparison of AT and ALT accuracies used the Obuchowski method.For the individual analysis, a total of 1250 patients were included and for the meta-analysis six studies (2017 patients) were included. The overall accuracy of AT for the diagnosis of any activity grade (Obuchowski measure=0.850) was significantly higher than the accuracy of ALT (Obuchowski measure=0.837; P=0.009). The updated standard meta-analysis confirmed the accuracy of AT (p0.0001) both in independent AUROC=0.79 (95% CI, 0.73-0.85) and in non independent studies AUROC=0.74 (95% CI, 0.67-0.81).The accuracy of AT for grading the necro-inflammatory activity of patients with HCV was significantly higher than ALT serum activity alone, the standard biomarker.
Published: 2010
Full Text: View/download PDF

28. Post-treatment liver stiffness measurement is not useful to predict hepatocellular carcinoma in HCV patients who achieve SVR

Author: V. Anne, Pierre-Henri Bernard, Faiza Chermak, M. Francois, S. Giovanna, Christophe Hézode, V. de Ledinghen, Sarah Shili, H. Jean-Baptiste, and Juliette Foucher
Subjects: medicine.medical_specialty, Hepatology, business.industry, medicine.disease, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Liver stiffness, 030220 oncology & carcinogenesis, Internal medicine, Hepatocellular carcinoma, medicine, 030211 gastroenterology & hepatology, Post treatment, business
Published: 2018
Full Text: View/download PDF

29. Sofosbuvir plus ribavirin and sofosbuvir plus daclatasvir-based regimens are suboptimal in genotype 2 patients: real-life experience

Author: Georges Haour, V. de Ledinghen, Dominique Larrey, Christophe Hézode, D. Celine, Pol Stanislas, J.-M. Pawlotsky, Tran Albert, Olivier Chazouillères, Metivier Sophie, M. Patrick, Didier Samuel, F. Helene, C. Fabrice, Fabien Zoulim, C. Stephane, and Jean-Pierre Bronowicki
Subjects: Oncology, medicine.medical_specialty, Daclatasvir, Hepatology, Sofosbuvir, business.industry, Ribavirin, chemistry.chemical_compound, chemistry, Internal medicine, Genotype, Medicine, business, medicine.drug
Published: 2018
Full Text: View/download PDF

30. Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C

Author: P. Couzigou, Wassil Merrouche, Laurent Castera, S. Djabarouti, Pascale Trimoulet, M.-C. Saux, Juliette Foucher, Dominique Breilh, and V. de Ledinghen
Subjects: Adult, Male, medicine.medical_specialty, Adolescent, viruses, Hepatitis C virus, Hepacivirus, Interferon alpha-2, medicine.disease_cause, Antiviral Agents, Gastroenterology, Polyethylene Glycols, Young Adult, Cmin, chemistry.chemical_compound, Pegylated interferon, Internal medicine, Ribavirin, Blood plasma, medicine, Humans, Pharmacology (medical), Prospective Studies, Prospective cohort study, Aged, Hepatology, business.industry, Interferon-alpha, virus diseases, Hepatitis C, Hepatitis C, Chronic, Middle Aged, Viral Load, biochemical phenomena, metabolism, and nutrition, medicine.disease, Recombinant Proteins, digestive system diseases, chemistry, Immunology, Female, business, Viral load, medicine.drug
Abstract: Summary Background The main goal of therapy in hepatitis C virus (HCV) infection is to achieve a sustained virological response (SVR). However, the impact of the pharmacological properties of ribavirin on the SVR has not been fully investigated. Aim To evaluate, through a prospective study, the association between ribavirin plasma level and SVR response in HCV patients treated with pegylated interferon (PEG-IFN) and ribavirin. Patients and methods Patients treated with PEG-IFN and ribavirin had plasmatic ribavirin dosage at weeks 4 and 12. SVR was evaluated 6 months after the end of treatment. Results At week 4, a strong correlation was found between HCV-RNA and Cmin of ribavirin plasma level (r = −0.376, P = 0.002) and AUC012h of ribavirin plasma level (r = −0.277, P = 0.018). At week 12, a strong correlation was found between HCV-RNA and Cmin of ribavirin plasma level (r = −0.384, P
Published: 2009
Full Text: View/download PDF

31. The tolerance and efficacy of a postponed retreatment with infliximab in Crohn’s disease primary responders

Author: Clément Subtil, Mathurin Kowo, D. Laharie, V. de Ledinghen, Edouard Chabrun, K. El Hanafi, and E. Chanteloup
Subjects: Adult, medicine.medical_specialty, Time Factors, Adolescent, Disease, Young Adult, Crohn Disease, Gastrointestinal Agents, Reference Values, Internal medicine, medicine, Humans, Pharmacology (medical), Young adult, Aged, Aged, 80 and over, Crohn's disease, Gastrointestinal agent, Hepatology, business.industry, Gastroenterology, Antibodies, Monoclonal, Middle Aged, medicine.disease, Infliximab, Surgery, Discontinuation, Clinical trial, Regimen, Treatment Outcome, Multivariate Analysis, Retreatment, business, medicine.drug
Abstract: Summary Background In Crohn’s disease (CD) patients naive to immunomodulators primary responding to infliximab (IFX) induction, maintenance with scheduled IFX or with immunomodulators is possible. The benefit of additional IFX infusions after failure of maintenance with immunomodulators is not known. Aim To assess the efficacy and factors associated with efficacy of postponed IFX retreatment. Methods All CD primary responders to an IFX induction regimen in maintenance with immunomodulators were retrospectively included when they received at least one additional IFX infusion after week 14. Efficacy was defined as clinical response at week 4 and absence of intolerance leading to discontinuation. Results Sixty-one patients were retreated with IFX with a 38-week median time from induction. Efficacy was achieved in 80% patients. Twelve patients had no clinical benefit: seven acute hypersensitivity reactions and five loss of response. By multivariate analysis, the only factor associated with no efficacy was a median time >50 weeks from induction to retreatment (odds ratio = 7.38; 95%CI: 1.38–39.59; P = 0.02). Conclusion Postponed retreatment with IFX in CD primary responders should be administered within 50 weeks after induction, for better efficacy and tolerance.
Published: 2009
Full Text: View/download PDF

32. Diagnostic non invasif de la fibrose hépatique : modalités pratiques d’utilisation des marqueurs sanguins et du FibroScan

Author: V. de Ledinghen and J. Vergniol
Subjects: Gynecology, medicine.medical_specialty, business.industry, Gastroenterology, medicine, General Medicine, business
Published: 2009
Full Text: View/download PDF

33. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients

Author: Juliette Foucher, Nathalie Salles, P. Dussarat, S. Villars, and V. de Ledinghen
Subjects: Adult, Liver Cirrhosis, Male, medicine.medical_specialty, Liver fibrosis, Population, Aspartate transaminase, Gastroenterology, Diabetes Complications, Liver disease, Fibrosis, Internal medicine, medicine, Humans, Aspartate Aminotransferases, Prospective Studies, education, Prospective cohort study, Aged, Aged, 80 and over, education.field_of_study, biology, Platelet Count, business.industry, General Medicine, Middle Aged, medicine.disease, biology.protein, Elasticity Imaging Techniques, Female, Transient elastography, Hepatic fibrosis, business, Biomarkers
Abstract: The objective of this study was to evaluate liver fibrosis using non-invasive methods in elderly patients.In a prospective two-day study, all consecutive patients of geriatric units were examined using transient elastography (FibroScan) and biochemical markers (Hepascore, Aspartate Transaminase (AST) to platelet ratio index [APRI], Forns score, FibroTest). Three groups of patients were included: elderly patients without liver disease (group A, 85.2+/-7.3 years); healthy younger control subjects without liver fibrosis (group B, 46.4+/-15.2 years); and elderly patients with confirmed liver disease (group C, 82.4+/-2.3 years).FibroScan) results in the elderly patients correlated well with fibrosis surrogates, but were more difficult to obtain than in the younger subjects. Mean liver stiffness was 6.1 kPa (group A) versus 4.9 kPa (group B) and versus 10.2 kPa (group C) (P0.0001). FibroTest results were 0.5 in group A versus 0.2 in group B, and versus 0.6 in group C (P0.0001). In group A, statistical analysis showed that diabetes was associated with advanced liver fibrosis (FibroScan)or = 9.5 kPa). A body mass index greater than 26kg/m2, age greater than 85 years, comorbidity score and polymedication were not associated with fibrosis.Although liver stiffness may be more difficult to assess in the elderly, FibroScan may nevertheless serve as a new, non-invasive method for detecting liver fibrosis in this population.
Published: 2009
Full Text: View/download PDF

34. Changes of non-invasive markers and FibroScan values during HCV treatment

Author: Eric Terrebonne, E. Chanteloup, Laurent Castera, V. de Ledinghen, P. Couzigou, Pierre-Henri Bernard, Juliette Foucher, Wassil Merrouche, R. Tournan, and J. Vergniol
Subjects: Adult, Liver Cirrhosis, Male, medicine.medical_specialty, Cirrhosis, Interferon alpha-2, Antiviral Agents, Severity of Illness Index, Gastroenterology, Cohort Studies, Virology, Internal medicine, Ribavirin, medicine, Humans, Prospective Studies, Prospective cohort study, Aged, Hepatitis, Hepatology, medicine.diagnostic_test, FibroTest, business.industry, Interferon-alpha, Hepatitis C, Middle Aged, medicine.disease, Recombinant Proteins, Treatment Outcome, Infectious Diseases, Liver, Liver biopsy, Elasticity Imaging Techniques, RNA, Viral, Female, Transient elastography, business, Biomarkers, Cohort study
Abstract: The recent advent of non-invasive methods for assessment of fibrosis allows serial assessments in all patients with hepatitis C. The aim of this prospective study was to evaluate changes in liver fibrosis, as measured with non-invasive methods, in a large cohort of HCV-infected patients with and without treatment. From May 2003 through March 2006, all previously untreated HCV-infected patients were enrolled in this study. Liver fibrosis was staged with FibroScan and Fibrotest at inclusion, then every year in untreated patients, and at the end of treatment and 6 months later in treated patients. The study population consisted of 416 patients, of whom 112 started treatment after enrolment. In the treatment group, FibroScan and Fibrotest values were significantly higher before and after treatment than in untreated patients at baseline and after 1 year. However, there was no significant difference between treated and untreated patients at the end of follow-up. FibroScan and Fibrotest values fell in all treated patients, whatever their virological response. In multivariate analysis, treatment was the only factor independently associated with a fall in the FibroScan value. In conclusion, whatever the virological response, treatment for HCV infection is associated with an improvement of FibroScan and Fibrotest values. Further studies are needed to compare these non-invasive methods with liver biopsy. These non-invasive methods, and especially FibroScan, should be useful for assessing treatment efficacy in clinical trials of new drugs.
Published: 2009
Full Text: View/download PDF

35. Évaluation non-invasive de la fibrose hépatique au cours de l’hépatite C

Author: Thierry Poynard, Claire Wartelle, V. de Ledinghen, and Eric Rosenthal
Subjects: Gynecology, medicine.medical_specialty, FibroTest, business.industry, Liver fibrosis, Gastroenterology, medicine, General Medicine, business
Abstract: Resume Depuis 2007, la Haute Autorite de Sante recommande l’utilisation soit du FibroScan soit du FibroTest soit de la ponction biopsie hepatique dans le bilan initial d’une hepatite chronique virale C sans co-morbidite. Ces methodes non invasives d’evaluation de la fibrose doivent toujours s’interpreter en fonction du contexte clinique et en connaissant les risques de faux positifs et de faux negatifs. Pour le FibroTest, les profils a risque sont surtout l’hemolyse, le syndrome de Gilbert et l’inflammation aigue. La realisation du FibroTest doit respecter les conditions pre-analytiques et analytiques des fabricants ainsi que les alertes generees par les algorithmes de securite. Le resultat de mesure d’elasticite hepatique doit lui aussi etre interprete en tenant compte du nombre de mesures valides, du pourcentage de reussite des mesures et de la dispersion des resultats. Il ne faut pas hesiter a recommencer un examen en cas de doute sur la qualite de celui-ci. Comme pour la ponction-biopsie du foie de 25 mm, le FibroTest et le FibroScan sont moins performants pour distinguer 2 stades de fibrose adjacents. Par contre, leurs performances sont tres bonnes pour le diagnostic de fibrose avancee par rapport a la fibrose non-avancee et pour le diagnostic de cirrhose.
Published: 2008
Full Text: View/download PDF

36. Foie et méthotrexate

Author: Edouard Chabrun, D. Laharie, V. de Ledinghen, P. Couzigou, E. Chanteloup, J. Vergniol, and Eric Terrebonne
Subjects: medicine.medical_specialty, medicine.diagnostic_test, business.industry, medicine.drug_class, Gastroenterology, General Medicine, Disease, medicine.disease, Antimetabolite, chemistry.chemical_compound, chemistry, Internal medicine, Rheumatoid arthritis, Diabetes mellitus, Psoriasis, Liver biopsy, Antifolate, medicine, Methotrexate, business, medicine.drug
Abstract: Methotrexate is proposed for the treatment of inflammatory disorders such as rheumatoid arthritis, psoriasis and Crohn's disease. The liver toxicity of methotrexate has been investigated and prolonged treatment can induce liver fibrosis. Moreover, alcohol consumption, diabetes and obesity are associated with liver fibrosis in patients treated with this drug. Therefore, liver fibrosis associated with methotrexate could be due to associated factors instead of methotrexate itself. Recommendations to monitor and diagnose methotrexate induced liver damage vary depending on the disease. Frequent evaluation of liver fibrosis with liver biopsy is recommended during therapy, especially in patients treated for psoriasis. Noninvasive methods, such as the FibroScan, could be useful for the assessment of liver fibrosis associated with methotrexate and hence, need further evaluation.
Published: 2008
Full Text: View/download PDF

37. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: A prospective study

Author: D. Laharie, Laurent Castera, V. de Ledinghen, Xavier Adhoute, P. Couzigou, Juliette Foucher, J. Vergniol, Eric Terrebonne, E. Chanteloup, B. Lovato, and Wassil Merrouche
Subjects: Liver Cirrhosis, Male, medicine.medical_specialty, Gastroenterology, Cohort Studies, Predictive Value of Tests, Fibrosis, Internal medicine, Humans, Medicine, Aspartate Aminotransferases, Cysteine, Prospective Studies, Prospective cohort study, Hemochromatosis, medicine.diagnostic_test, business.industry, Homozygote, Age Factors, General Medicine, Middle Aged, medicine.disease, Liver, Predictive value of tests, Liver biopsy, Ferritins, Elasticity Imaging Techniques, Tyrosine, Female, business, Hepatic fibrosis, Transient elastography, Biomarkers, Follow-Up Studies, Cohort study
Abstract: Summary Background The role of hepatic iron overload in the development of hepatic fibrosis in patients with hemochromatosis is well-established. Transient elastography (FibroScan) is a new noninvasive, rapid, reproducible bedside method, allowing assessment of liver fibrosis by measuring liver rigidity. Objectives The aim of this prospective study was to evaluate liver fibrosis with FibroScan and other noninvasive biochemical methods in patients with hemochromatosis (C282Y homozygosity) compared with control patients. Patients and methods From January 2004 through October 2006, all consecutive patients with hemochromatosis were evaluated for liver fibrosis using noninvasive methods (FibroScan and biochemical markers). These patients were compared with patients who had chronic cytolysis and no fibrosis on liver biopsy. Results One hundred and three consecutive patients (57 cases and 46 controls) were fully investigated. Median FibroScan values were similar in both groups, 5.20 kPa versus 4.9 kPa, respectively. No differences were observed between cases and controls for all biochemical markers. A strong correlation was observed between FibroScan and many biochemical markers, although ferritin levels did not correlate with FibroScan values. The prevalence of patients with FibroScan values greater than 7.1 kPa (cut-off level for significant fibrosis) was 22.8% in patients with hemochromatosis and 0% in the controls ( P Conclusion FibroScan and biochemical markers could be reliable noninvasive methods for detecting liver fibrosis in patients with hemochromatosis. Such patients have high FibroScan values more often than do control patients. Further longitudinal and prospective studies are necessary to confirm these preliminary data.
Published: 2008
Full Text: View/download PDF

38. Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype

Author: Maria Winnock, Marc-Arthur Loko, V. de Ledinghen, François Dabis, Laurent Castera, Pascale Trimoulet, B. Le Bail, P. Coffie, and Didier Neau
Subjects: medicine.medical_specialty, Pathology, Hepatology, medicine.diagnostic_test, business.industry, Fatty liver, Gastroenterology, virus diseases, Hepatitis C, Odds ratio, medicine.disease, Liver biopsy, Internal medicine, Immunopathology, Coinfection, Medicine, Pharmacology (medical), Steatosis, business, Body mass index
Abstract: Background Significance of steatosis in HIV-HCV coinfection remains controversial. Aim To compare the prevalence and predictors of hepatic steatosis between HIV-HCV and HCV patients matched for steatosis known determinants. Methods A total of 564 HCV-naive patients undergoing liver biopsy were studied: 137 with HIV-HCV coinfection and 427 with HCV monoinfection, among whom 137 were matched for age, gender, body mass index and HCV genotype. Results Steatosis of any grade (67.1% vs. 41.6%, P < 0.0001), mixed steatosis (55.4% vs. 21.1%, P < 0.0001), severe histological activity (A2-A3: 78.1% vs. 55.5%, P < 0.0001) and severe fibrosis (F3-F4: 33.1% vs. 15.3%, P < 0.0001) were significantly more common in coinfected than in matched monoinfected patients. In multivariate analysis, steatosis was associated only with severe histological activity [odds ratio (OR): 3.1 (95% CI: 1.3-7.1)] in coinfected patients and with elevated body mass index [OR; 1.3 (1.1-1.5)], HCV genotype 3 [OR: 5.6 (2.3-13.9)], severe histological activity [OR: 3.1 (1.3-7.3)] and severe fibrosis [OR: 4.7 (1.3-17.3)] in monoinfected patients. Conclusions Steatosis is significantly more common and severe in HIV-HCV coinfected than in HCV monoinfected French patients, even after matching for body mass index and HCV genotype. Steatosis is associated only with severe histological activity in coinfected patients and with previously reported factors in monoinfected patients, thus suggesting different underlying mechanisms.
Published: 2007
Full Text: View/download PDF

39. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation

Author: Philippe Halfon, Djamila Messous, V. Ratziu, Frédéric Charlotte, Yves Benhamou, B. Le Bail, Mona Munteanu, Laurent Castera, Thierry Poynard, Marc Bourlière, and V. de Ledinghen
Subjects: medicine.medical_specialty, Hepatology, Receiver operating characteristic, medicine.diagnostic_test, business.industry, FibroTest, Liver fibrosis, Gastroenterology, Diagnostic evaluation, medicine.disease, Fibrosis, Biopsy, medicine, Pharmacology (medical), In patient, Radiology, Hepatic fibrosis, business
Abstract: SUMMARY Background The area under the receiver operating characteristic (ROC) curve is widely used as an estimate of the diagnostic value for fibrosis markers. Biopsy length and fragmentation are known as risk factors of false positive or false negative of biopsy but their quantitative impact on area under the receiver operating characteristic curve variability has not been assessed. Aim To assess these relationships to better compare the fibrosis markers. Methods The area under the ROC curves of FibroTest for the diagnosis of fibrosis was estimated in patients with chronic hepatitis C using an integrated database including 1312 patients with FibroTest and biopsy. To take into account the biopsy length, we used two adjustment factors: one in which an observed area under the ROC curve could be adjusted according to the relative area under the receiver operating characteristic curve of a biopsy of a given length vs. the entire liver and one taking into account the prevalence of each fibrosis stage defining advanced and non-advanced fibrosis.
Published: 2007
Full Text: View/download PDF

40. Sexual quality of life is impaired in patients with chronic hepatitis C

Author: V. De Ledinghen, Juliette Foucher, S Duc, G Hou, C Fabères, Faiza Chermak, N Souakri, A Lafournière, F Chenus, J. Vergniol, and Jean-Baptiste Hiriart
Subjects: Adult, Male, medicine.medical_specialty, Urology, Female sexual dysfunction, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Internal medicine, Sexual medicine, medicine, Humans, 030212 general & internal medicine, Propensity Score, Aged, Gynecology, business.industry, Hepatitis C, Odds ratio, Hepatitis C, Chronic, Middle Aged, medicine.disease, Transplantation, Erectile dysfunction, Sexual dysfunction, Cross-Sectional Studies, Case-Control Studies, Quality of Life, 030211 gastroenterology & hepatology, Female, medicine.symptom, business, Sexuality
Abstract: Chronic hepatitis C (CHC) patients often have altered quality of life. Few data are available about sexual impairment (SI) in CHC. From 2011 to 2013, we included consecutive CHC outpatients. Exclusion criteria were: antiviral therapy, co-infection, age 75, transplantation, alcohol consumption, Eastern Cooperative Oncology Group >1. Non-CHC subjects were healthy blood donors. Sexual questionnaires for men and women were adapted from the International Index of Erectile Function and Female Sexual Function Index, respectively, and concerned the past 30 days. Two hundred eighty-one patients were compared with 1086 blood donors. SI was more frequent in CHC patients. Men with CHC had worse desire, confidence, erections, climax and satisfaction (P
Published: 2015

41. O109 : Treatment of severe HCV-recurrence after liver transplantation using sofosbuvir-based regimens: The ANRS CO23 CUPILT study

Author: G.-P. Pageaux, Jean Charles Duclos-Vallée, F. Durand, L. D’Alteroche, Valérie Canva, H. Danjou, Audrey Coilly, Vincent Leroy, Danielle Botta-Fridlund, Claire Fougerou-Leurent, Pauline Houssel-Debry, Abou Diallo, Fabio Conti, Nassim Kamar, V. Di Martino, S. Radenne, Christophe Duvoux, A. Rohel, V. de Ledinghen, Jérôme Dumortier, Département d'hépatologie, Hospices Civils de Lyon (HCL), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Multiorgan Transplantation, and CHU Toulouse [Toulouse]
Subjects: medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Hcv recurrence, Liver transplantation, Gastroenterology, 3. Good health, Internal medicine, medicine, business, ComputingMilieux_MISCELLANEOUS, medicine.drug
Abstract: International audience; no abstract
Published: 2015
Full Text: View/download PDF

42. G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort

Author: Nassim Kamar, Jérôme Dumortier, Pascal Lebray, P. Perré, C. Silvain, Jean Charles Duclos-Vallée, Vincent Leroy, Audrey Coilly, Valérie Canva, V. Di Martino, Alain Renault, Pauline Houssel-Debry, G.-P. Pageaux, Danielle Botta-Fridlund, H. Danjou, C. Fougerou, Sylvie Radenne, Christophe Moreno, L. D’Alteroche, V. de Ledinghen, Camille Besch, Rodolphe Anty, Christophe Duvoux, A. Rohel, Service de Pharmacologie [Rennes], CHU Pontchaillou [Rennes], Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Département d'hépatologie, Hospices Civils de Lyon (HCL), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Multiorgan Transplantation, CHU Toulouse [Toulouse], Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: medicine.medical_specialty, Daclatasvir, Hepatology, Sofosbuvir, business.industry, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Liver transplantation, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Immunology, Cohort, medicine, 030211 gastroenterology & hepatology, business, ComputingMilieux_MISCELLANEOUS, medicine.drug
Abstract: International audience; no abstract
Published: 2015
Full Text: View/download PDF

43. G08 : Incidence of hepatocellular carcinoma (HCC) and complications in alcoholic compensated cirrhosis. Preliminary results of a multicenter prospective French and belgian cohort (INCA Cirral)

Author: Xavier Amiot, Cendrine Chaffaut, Jean Charles Duclos-Vallée, I. Archambaud, Dominique Roulot, Albert Tran, Eric Nguyen-Khac, Odile Goria, Violaine Ozenne, Romain Moirand, Jean-Pierre Zarski, Nicolas Carbonell, V. de Ledinghen, Stanislas Pol, Sylvie Chevret, Alexandre Louvet, Christophe Moreno, V. Bourcier, Thong Dao, Jean-Marc Perarnau, Jean Henrion, Nathalie Ganne, Frédéric Oberti, Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier St. Joseph, Department of Gastroenterology, Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Subjects: 0303 health sciences, medicine.medical_specialty, Cirrhosis, [ SDV ] Life Sciences [q-bio], Hepatology, 030309 nutrition & dietetics, business.industry, Incidence (epidemiology), [SDV]Life Sciences [q-bio], 030209 endocrinology & metabolism, medicine.disease, Gastroenterology, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Hepatocellular carcinoma, Cohort, medicine, business, ComputingMilieux_MISCELLANEOUS
Abstract: International audience; no abstract
Published: 2015
Full Text: View/download PDF

44. P1266 : Human albumin use in cirrhotic patients in France: Results of the national 'Albu-live' survey

Author: Jacques Denis, Xavier Amiot, C. Bureau, D. Valla, Isabelle Ollivier-Hourmand, N. Carbonnel, Brigitte Bernard-Chabert, Alexandre Louvet, Olivier Chazouillères, Jean-Claude Trinchet, Alexandre Pariente, Laurent Alric, D. Zanditenas, Christophe Renou, Thierry Paupard, Vincent Leroy, G.-P. Pageaux, Stanislas Pol, Thierry Poynard, P. Mathurin, Jean-Pierre Zarski, L. Bettan, B. Lesgourgues, V. de Ledinghen, Vincent Jouannaud, Denis Ouzan, T. Fontanges, Michael Bismuth, Armando Abergel, H. Labadie, L. Elkrief, Thierry Thevenot, Dominique Thabut, Thong Dao, K. Dupont, R. Bader, Xavier Causse, N. Talbodec, Gilles Macaigne, Bertrand Hanslik, I. Rosa-Hézode, P. Nahon, Armand Garioud, Hortensia Lison, Arnaud Pauwels, Dominique Guyader, Jean François Cadranel, Philippe Sogni, Agents pathogènes et inflammation - UFC (EA 4266) ( API ), Université de Franche-Comté ( UFC ), Hydrosystèmes et bioprocédés ( UR HBAN ), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture ( IRSTEA ), Institut d'astrophysique spatiale ( IAS ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Service d'hépatologie médicale [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Matière et Systèmes Complexes ( MSC ), Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ), Service des maladies du foie, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-Centre Hospitalier Universitaire de Rennes, Foie, métabolismes et cancer, Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Hydrosystèmes et bioprocédés (UR HBAN), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Institut d'astrophysique spatiale (IAS), Université Paris-Sud - Paris 11 (UP11)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Matière et Systèmes Complexes (MSC (UMR_7057)), Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire [Rennes]-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Hydrosystèmes et Bioprocédés (UR HBAN), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Université Paris-Sud - Paris 11 (UP11)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Centre National d’Études Spatiales [Paris] (CNES), Matière et Systèmes Complexes (MSC), Service des maladies du foie [CHU Rennes], Centre Hospitalier Universitaire [Rennes], and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
Subjects: medicine.medical_specialty, Hepatology, [ SDV ] Life Sciences [q-bio], business.industry, [SDV]Life Sciences [q-bio], Emergency medicine, medicine, Human albumin, Intensive care medicine, business, ComputingMilieux_MISCELLANEOUS, 3. Good health
Abstract: International audience; no abstract
Published: 2015
Full Text: View/download PDF

45. LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program

Author: Isabelle Rosa, V. de Ledinghen, Jean-Pierre Bronowicki, C. Silvain, Danielle Botta-Fridlund, Christophe Hézode, Yacia Bennai, Raoudha Akremi, M. Bourlière, Eric Nguyen-Khac, Pascal Lebray, I. Hubert-Fouchard, Dominique Larrey, Vincent Leroy, Hélène Fontaine, V. Di Martino, L. D’Alteroche, Dominique Guyader, Fabien Zoulim, Nathalie Boyer, Larysa Fedchuk, Fabrice Carrat, Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Matière et Systèmes Complexes (MSC), Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Service d'Hépato-gastroentérologie, Assistance Publique - Hôpitaux de Marseille (APHM), Service des maladies du foie [CHU Rennes], Centre Hospitalier Universitaire [Rennes], Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Amiens-Picardie, Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 (GRAP), Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Hôpital Henri Mondor-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Nice Sophia Antipolis (... - 2019) (UNS), Matière et Systèmes Complexes (MSC (UMR_7057)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Service des maladies du foie, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Centre Hospitalier Universitaire [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Lyon (CRCL), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire [Rennes]-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Epidémiologie, Systèmes dínformation et modélisation (ESIM), and CHU Saint-Antoine [APHP]
Subjects: medicine.medical_specialty, Daclatasvir, Hepatology, Sofosbuvir, business.industry, Ribavirin, [SDV]Life Sciences [q-bio], Compassionate Use, Interim analysis, Virology, 3. Good health, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, 030220 oncology & carcinogenesis, Internal medicine, Genotype, Medicine, 030211 gastroenterology & hepatology, In patient, business, ComputingMilieux_MISCELLANEOUS, medicine.drug
Abstract: International audience; no abstract
Published: 2015
Full Text: View/download PDF

46. LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather

Author: François Habersetzer, Dominique Larrey, Vincent Leroy, Stanislas Pol, Fabien Zoulim, Patrick Marcellin, Christophe Hézode, Hélène Fontaine, Albert Tran, Laurent Alric, C. Dorival-Mouly, Didier Samuel, V. de Ledinghen, G. Haour, S. Metivier, Isabelle Rosa, Mélanie Simony, Alpha Diallo, Yves Benhamou, Véronique Loustaud-Ratti, Fabrice Carrat, Ghassan Riachi, S. Lucier, Anne Minello, I. Hubert-Fouchard, M. Bourlière, Dominique Guyader, P. Mathurin, Jean-Pierre Bronowicki, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Service d'Hépato-gastroentérologie, Assistance Publique - Hôpitaux de Marseille (APHM), Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Matière et Systèmes Complexes (MSC), Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalo-Universitaire de Grenoble (CHU de Grenoble), CHU Grenoble, Hôpital Saint Eloi, Cellules souches normales et cancéreuses, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Nice (CHU Nice), Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Pathologies biliaires, fibrose et cancer du foie [CRSA], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Les Hôpitaux Universitaires de Strasbourg (HUS), Institut de Recherche sur les Maladies Virales et Hépatiques (IVH), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Lorraine (UL), Service des maladies du foie [CHU Rennes], Centre Hospitalier Universitaire [Rennes], Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Hôpital Dupuytren [CHU Limoges], Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques (RESINFIT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Intercommunal de Créteil (CHIC), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Hôpital Cochin [AP-HP], Faculte ́deMe ́decine Rene ́ Descartes, Universite ́ Paris, Unite ́ Mixte 3, Paris, France, CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de Recherche en Cancérologie de Lyon (CRCL), Matière et Systèmes Complexes (MSC (UMR_7057)), Animal et gestion intégrée des risques (Cirad-Bios-UPR 22 AGIRs), Département Systèmes Biologiques (Cirad-BIOS), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad), Hôpital Beaujon-Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service des maladies du foie, Centre Hospitalier Universitaire [Rennes]-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Epidémiologie, Systèmes dínformation et modélisation (ESIM), CHU Saint-Antoine [APHP], Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Service de Gastro-entérologie - Hépatologie [Purpan], CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Pathologies biliaires, fibrose et cancer du foie [CHU Saint-Antoine], Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC), Hôpital Purpan [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges, Hôpital Charles Nicolle [Rouen]-CHU Rouen, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées
Subjects: Simeprevir, medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, Ribavirin, [SDV]Life Sciences [q-bio], medicine.disease, 3. Good health, sofosbuvir-based, Liver disease, chemistry.chemical_compound, HCV genotype 4-mono-infected, chemistry, Internal medicine, Cohort, Genotype, medicine, Observational study, business, Adverse effect, anrs CO22 hepather, ComputingMilieux_MISCELLANEOUS, medicine.drug
Abstract: International audience; Introduction:Real-life results of the Sofosbuvir (SOF)/Simeprevir(SIM) combination have been extensively reported in genotype 1-infected patients but there are few or no data regarding genotype 4-infected patients for the SOF/SIM or the SOF-Daclatasvir (DCV)combinations. In January 2015, more than 3003 patients of theFrench observational cohort ANRS CO22 HEPATHER were given thenew oral antivirals in 32 centers: we report the preliminary resultsof the Sofosbuvir-based combinations with DCV or SIM, with orwithout ribavirin (RBV), in Genotype 4-infected patients.Material and Methods:Demographics, history of liver disease werecollected at entry in the cohort. Clinical, adverse events, andvirological data were collected throughout treatment and post-treatment follow-up.
Published: 2015
Full Text: View/download PDF

47. P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic

Author: Stanislas Pol, Dominique Larrey, Hélène Fontaine, Valérie Canva, A. Tran, Christophe Hézode, Armando Abergel, Yoann Barthe, Laurent Alric, Thong Dao, Pierre Attali, J.-M. Pawlotsky, Damien Lucidarme, Didier Samuel, Patrice Cacoub, S. Metivier, Thierry Poynard, Paul Calès, V. de Ledinghen, Véronique Loustaud-Ratti, M. Bourlière, Isabelle Rosa, Fabrice Carrat, Véronique Grando-Lemaire, Fabien Zoulim, V. Di Martino, C. Dufour, Ghassan Riachi, Pierre-Henri Bernard, Jean-Pierre Bronowicki, Isabelle Portal, Lawrence Serfaty, T. Fontanges, Patrick Marcellin, J.-J. Raabe, Dominique Guyader, Xavier Causse, Jean-Pierre Zarski, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de recherche sur les Ions, les MAtériaux et la Photonique (CIMAP - UMR 6252), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche sur les Matériaux Avancés (IRMA), Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Rouen Normandie (UNIROUEN), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Service d'hépatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépato-gastroentérologie, Assistance Publique - Hôpitaux de Marseille (APHM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut d'astrophysique spatiale (IAS), Université Paris-Sud - Paris 11 (UP11)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Centre National d’Études Spatiales [Paris] (CNES), Service des maladies du foie [CHU Rennes], Centre Hospitalier Universitaire [Rennes], Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pitié-Salpêtrière [AP-HP], SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques (ICAT), Université d'Angers (UA), Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche en Cancérologie de Montpellier ( IRCM - U1194 Inserm - UM ), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Centre de recherche sur les Ions, les MAtériaux et la Photonique ( CIMAP - UMR 6252 ), Centre National de la Recherche Scientifique ( CNRS ) -Ecole Nationale Supérieure d'Ingénieurs de Caen ( ENSICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de biologie et chimie des protéines [Lyon] ( IBCP ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Hôpital Beaujon, Assistance Publique - Hôpitaux de Marseille ( APHM ), Service d'hépatologie [Saint-Antoine], Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Institut d'astrophysique spatiale ( IAS ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Service des maladies du foie, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-Centre Hospitalier Universitaire de Rennes, Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pitié-Salpêtrière [APHP], Interactions cellulaires et applications thérapeutiques ( ICAT ), Université d'Angers ( UA ) -CHU Angers-CRLCC Paul Papin-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), CIRAD, UPR AGIRs, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Epidémiologie, Systèmes dínformation et modélisation ( ESIM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Unité de Santé Publique, Assistance publique - Hôpitaux de Paris - AP-HP (FRANCE)-CHU Saint-Antoine [APHP], Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université Paris-Sud - Paris 11 (UP11)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Centre Hospitalier Universitaire [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Service d'hépatologie [CHU Saint-Antoine], Centre Hospitalier Universitaire [Rennes]-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou
Subjects: 0303 health sciences, Pediatrics, medicine.medical_specialty, Hepatology, [ SDV ] Life Sciences [q-bio], business.industry, [SDV]Life Sciences [q-bio], Treatment experienced, 3. Good health, Telaprevir, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Boceprevir, Cohort, medicine, 030211 gastroenterology & hepatology, business, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, medicine.drug
Abstract: International audience; no abstract
Published: 2015
Full Text: View/download PDF

48. LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather

Author: Christophe Hézode, Hélène Fontaine, Yves Benhamou, Jean-Pierre Bronowicki, P. Mathurin, Ventzislava Petrov-Sanchez, Jean-Pierre Zarski, J.-J. Raabe, J. Gournay, Véronique Loustaud-Ratti, V. de Ledinghen, Olivier Chazouillères, Jean-Claude Trinchet, Dominique Guyader, C. Dorival-Mouly, P. Nahon, Isabelle Rosa, S. Lucier, M. Bourlière, Dominique Larrey, François Raffi, Albert Tran, Patrick Marcellin, S. Metivier, Ghassan Riachi, Anne Minello, I. Hubert-Fouchard, Abou Diallo, Stanislas Pol, Fabien Zoulim, Fabrice Carrat, Laurent Alric, Didier Samuel, Xavier Causse, Service d'hépatologie médicale [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Service d'Hépato-gastroentérologie, Assistance Publique - Hôpitaux de Marseille ( APHM ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de biologie et chimie des protéines [Lyon] ( IBCP ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ), Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Service d'hépatologie, Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Hôpital Beaujon, Service des maladies du foie, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-Centre Hospitalier Universitaire de Rennes, Foie, métabolismes et cancer, Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes ( CHU Nantes ), Institut de Recherche en Cancérologie de Montpellier ( IRCM - U1194 Inserm - UM ), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Unité de Santé Publique, Assistance publique - Hôpitaux de Paris - AP-HP (FRANCE)-CHU Saint-Antoine [APHP], Epidémiologie, Systèmes dínformation et modélisation ( ESIM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance Publique - Hôpitaux de Marseille (APHM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service des maladies du foie [CHU Rennes], Centre Hospitalier Universitaire [Rennes], Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Centre Hospitalier Universitaire [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Saint-Antoine [APHP], Epidémiologie, Systèmes dínformation et modélisation (ESIM), and Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Hôpital Henri Mondor-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: medicine.medical_specialty, Daclatasvir, Hepatology, Sofosbuvir, [ SDV ] Life Sciences [q-bio], business.industry, [SDV]Life Sciences [q-bio], 3. Good health, Hcv genotype 1, Internal medicine, Cohort, Medicine, Observational study, business, ComputingMilieux_MISCELLANEOUS, medicine.drug
Abstract: International audience; no abstract
Published: 2015
Full Text: View/download PDF

49. Lifestyle changes and beliefs regarding disease severity in patients with chronic hepatitis C

Author: Aymery Constant, Laurent Castera, Patrice Couzigou, V. de Ledinghen, and P‐H. Bernard
Subjects: Adult, Male, medicine.medical_specialty, Cirrhosis, Culture, Disease, Anxiety, Virology, Internal medicine, medicine, Humans, Prospective Studies, Prospective cohort study, Life Style, Hepatology, business.industry, Hepatitis C, Odds ratio, Hepatitis C, Chronic, Middle Aged, medicine.disease, Infectious Diseases, Sex life, Physical therapy, Female, medicine.symptom, business, Viral load
Abstract: Summary. The aim of this prospective study was to investigate beliefs regarding disease severity and lifestyle changes following hepatitis C diagnosis in patients with chronic hepatitis C (CHC). One hundred and eighty-five consecutive CHC patients were interviewed by means of self-questionnaires exploring several aspects of their disease. Most patients (93%) identified cirrhosis and liver cancer as the two main complications of CHC. More than half of patients (59%) thought that CHC was always associated with a fatal outcome whereas 3% thought that they would stay healthy. HCV viral load was the most commonly reported factor associated with disease severity. Sex life changes were reported by 107 patients (58%) whereas dietary intake changes were reported by 88 patients (48%). In multivariate analysis, changes in sex life were associated with male gender [odds ratio (OR): 2.57, 95% CI: 1.30–5.08, P
Published: 2006
Full Text: View/download PDF

50. The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort)

Author: Patrick Marcellin, Fabien Zoulim, A. Tran, Ventzislava Petrov-Sanchez, V. Bourcier, Paul Calès, V. de Ledinghen, Dominique Roulot, Françoise Roudot-Thoraval, Stanislas Pol, Denis Ouzan, M. Bourlière, Laurent Alric, Jean-Pierre Bronowicki, Jean-Pierre Zarski, P. Nahon, Dominique Guyader, Dominique Thabut, Ghassan Riachi, Jean-Marie Péron, Dominique Larrey, Richard Layese, L. Corvy, C. Bureau, and P. Mathurin
Subjects: medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Internal medicine, Cohort, medicine, Portal hypertension, In patient, medicine.disease, business, Gastroenterology
Published: 2016
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

170 results on '"V. de Ledinghen"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources